You are here: Industry Insights > AstraZeneca

News List

AstraZeneca Pharma India files writ petition in Delhi High Court against NPPA demand notice expresspharma
July 01, 2021
The notice of demand alleges that the company has overcharged about Rs 157.38 crore from March 8, 2019 to January 31, 2021, for Tagrisso (Osimertinib) 80 mg tablets.
A Single Dose of Vaxzevria Induced Immunity for One Year, Second and Third Dose Increase Response americanpharmaceuticalreview
June 30, 2021
Oxford-led COV001 and COV002 trials showed that Vaxzevria induced a strong immune response following a long second dose interval (up to 45 weeks) and after a third booster dose.
AstraZeneca Appoints Dr. Susan Galbraith as Executive Vice President, Oncology Research & Development americanpharmaceuticalreview
June 30, 2021
AstraZeneca has appointed Dr. Susan Galbraith to lead Oncology Research & Development. Her appointment follows the passing of José Baselga earlier this year.
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome firstwordpharma
June 30, 2021
Healthcare professionals including infectious disease physicians, family physicians, emergency room physicians, hematologists, neurologists, pharmacists, public health officials, nurses and nurse practitioners, and healthcare professionals at identified p
AZ doses first participants with COVID-19 variant vaccine pharmatimes
June 29, 2021
AstraZeneca (AZ) has announced that the first participants have been vaccinated as part of a Phase II/III trial testing a new COVID-19 variant vaccine – AZD2816.
Update on AZD7442 STORM CHASER Trial in Post-Exposure Prevention of Symptomatic COVID-19 drugs
June 29, 2021
AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
Analysis shows stronger immunity by delaying AstraZeneca COVID-19 vaccine doses firstwordpharma
June 29, 2021
A sub-analysis from two studies indicates that a long interval between the first and second doses of AstraZeneca's COVID-19 vaccine Vaxzevria does not compromise immune response after a late second dose, while a third dose continues to boost antibodies.
Japan mulls approving AstraZeneca COVID vaccine for people 18 and over firstwordpharma
June 24, 2021
According to sources, Japan is considering approving the use of AstraZeneca's COVID-19 vaccine for people aged 18 or over, as reported Kyodo News+ on Wednesday.
Koselugo Approved in EU for Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas americanpharmaceuticalreview
June 23, 2021
AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) ...
EU gets partial win in AstraZeneca Covid-19 vaccine supply case pharmaceutical-technology
June 23, 2021
The Court of First Instance in Brussels, Belgium, has ordered AstraZeneca to supply 80.2 million doses of its Covid-19 vaccine by 27 September, representing only a partial win for the EU.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page